Jazz Pharmaceuticals plc (JAZZ)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-14. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 9.01% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Ziihera’s FDA Win and Leadership Change Might Change The Case For Investing In Jazz Pharmaceuticals (JAZZ)
- Jazz Pharmaceuticals gets Cramer's vote of confidence
- CNBC's Becky Quick to Moderate CEO Leadership Dialogue on the Next Decade of Rare Disease at the NORD Breakthrough Summit
- Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks
- Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands
- Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?
- Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet
- Jazz Pharmaceuticals (JAZZ) Eyes Ziihera Trials In Breast Colorectal And Lung Cancer
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Jazz Pharmaceuticals plc.
Full JAZZ Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.